NextCell welcomes Consensus Sverige Selectas as a shareholder
The Board of Directors of NextCell Pharma AB (”NextCell or the ”Company”) has today, based on the authorization granted by the Annual General Meeting held on 24 November 2020, resolved on a directed issue of 666,666 new shares (the “Share Issue”) to Consensus Sverige Select (”Consensus”). The subscription price in the share issue amounts to SEK 15 per new share and the Company receives approximately SEK 10 million in issue proceeds.
The Board of Directors of NextCell has today, based on the authorization granted by the Annual General Meeting held on 24 November 2020, resolved on the Share Issue. The Share Issue comprises 666,666 new shares at a subscription price of SEK 15 per new share, which means that the Company will receive approximately SEK 10 million in issue proceeds. The subscription price of SEK 15 has been determined by the Company's Board of Directors after negotiations with Consensus and it is the Board of Directors’ assessment that the subscription price accurately reflects current market conditions and demand. The Share Issue’s purpose and the reason for the deviation from the shareholders' preferential rights is to broaden the shareholder base and the to finance the Company’s investment in its own production facility, as communicated by a press release on 2 March 2021.
Through the Share Issue, the number of outstanding shares and votes in the Company will increase by 666,666 shares from 33,712,857 till 34,379,523 shares. The share capital will increase by SEK SEK 136,666.53 from SEK 6,911,135.685 to SEK 7,047,802.22. The Share Issue entails a dilution for existing shareholders of approximately 1.94 percent of the number of shares and votes in the Company.
This information is such information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 31 March 2021, 08.40 CET.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
Website:
www.nextcellpharma.com, www.cellaviva.se
www.cellaviva.dk
About NextCell Pharma AB
NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.